Candonilimab Plus Bevacizumab
Showing 1 - 25 of 2,190
Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)
Withdrawn
- Hepatocellular Carcinoma
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Jun 1, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)
Recruiting
- Hepatocellular Carcinoma
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Feb 26, 2023
Locally Advanced Cervical Cancer Trial in Chongqing (Candonilimab(AK104), EBRT, BT)
Recruiting
- Locally Advanced Cervical Cancer
- Candonilimab(AK104)
- +2 more
-
Chongqing, CHN, ChinaChongqing university Cancer Hospital
Jan 15, 2023
Esophageal Squamous Cell Carcinoma Trial in Anyang, Zhengzhou (AK104, nab-paclitaxel, carboplatin)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- AK104, nab-paclitaxel, carboplatin
-
Anyang, Henan, China
- +1 more
Jun 1, 2023
Gastric Cancer Trial in Tianjin (AK104, Apatinib, Paclitaxel)
Recruiting
- Gastric Cancer
- AK104
- +3 more
-
Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
May 7, 2023
Patients With HHT. Follow up BABH
Completed
- Hemorrhagic Hereditary Telangiectasia
- HHT
- bevacizumab treatment
-
Angers, France
- +2 more
Sep 8, 2023
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable Trial in Seoul (Atezolizumab plus
Recruiting
- Hepatocellular Carcinoma
- +4 more
- Atezolizumab plus bevacizumab, combined EBRT to vascular invasion
- Atezolizumab plus bevacizumab
-
Seoul, Korea, Republic ofAsan Medical Center
Aug 7, 2023
Brain Metastases Trial (Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Stereotactic Radiation Therapy)
Not yet recruiting
- Brain Metastases
- Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)
- Stereotactic Radiation Therapy
- (no location specified)
Jun 2, 2023
Hepatocellular Carcinoma Trial in Nanjing, Shanghai (QL1706, Bevacizumab, Oxaliplatin injection)
Not yet recruiting
- Hepatocellular Carcinoma
- QL1706
- +4 more
-
Nanjing, Jiangsu, China
- +1 more
Jul 28, 2023
Glioblastoma Trial (plasma collection)
Not yet recruiting
- Glioblastoma
- plasma collection
- (no location specified)
Aug 18, 2023
Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Tumors Trial in Worldwide (biological, drug, other)
Recruiting
- Ovarian Cancer
- +2 more
- Pembrolizumab
- +4 more
-
Phoenix, Arizona
- +178 more
Jan 25, 2023
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Recruiting
- Neurofibromatosis 2
- Bevacizumab Zirconium Zr-89
-
Leiden, Zuid-Holland, NetherlandsLeiden University Medical Center
Jan 5, 2023
Colorectal Cancer Trial (HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV,
Not yet recruiting
- Colorectal Cancer
- HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
- HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
- (no location specified)
Jul 13, 2023
Metastatic Microsatellite-stable Colorectal Cancer Trial in China (Experimental drug, Control Rx)
Recruiting
- Metastatic Microsatellite-stable Colorectal Cancer
- Experimental drug
- Control Rx
-
Hefei, Anhui, China
- +11 more
Mar 13, 2023
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib
Not yet recruiting
- Ovarian Cancer
- +4 more
- Fluzoparib Capsules
- Bevacizumab
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Cetntre
Sep 25, 2023
Carcinoma, Ovarian Epithelial Trial in San Fermo Della Battaglia, Padova (Olaparib, Bevacizumab)
Recruiting
- Carcinoma, Ovarian Epithelial
-
San Fermo Della Battaglia, Como, Italy
- +1 more
Nov 2, 2023
Metastatic Breast Cancer Trial in Chuo-ku, Nihonbashi, Koami-cho (Paclitaxel, Bevacizumab, Letrozole)
Completed
- Metastatic Breast Cancer
- Paclitaxel
- +7 more
-
Chuo-ku, Nihonbashi, Koami-cho, Tokyo, JapanJapan Breast Cancer Research Group
Aug 2, 2022
Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)
Not yet recruiting
- Cervical Cancer
- Recombinant humanized anti-PD-1 monoclonal antibody injection
- +4 more
-
Wuhan, Hubei, ChinaTongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation Trial (Onvansertib, FOLFIRI, Bevacizumab)
Not yet recruiting
- Metastatic Colorectal Cancer
- +2 more
- Onvansertib
- +3 more
- (no location specified)
Oct 24, 2023
Hepatocellular Carcinoma Trial in Seoul (Lenvatinib)
Recruiting
- Hepatocellular Carcinoma
-
Seoul, Korea, Republic ofAsan Medical Center
Nov 14, 2023
Carcinoma, Hepatocellular Trial in Worldwide (Relatlimab, Nivolumab, Bevacizumab)
Recruiting
- Carcinoma, Hepatocellular
- Relatlimab
- +3 more
-
Los Angeles, California
- +62 more
Feb 1, 2023
Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation Trial in Seoul (Early response evaluation)
Recruiting
- Hepatocellular Carcinoma
- +2 more
- Early response evaluation
-
Seoul, Korea, Republic ofSeoul National University Hospital
Feb 28, 2023
Metastatic Colorectal Cancer Trial in Guangzhou (Fruquintinib alternating with Bevacizumab plus Capecitabine, Bevacizumab plus
Recruiting
- Metastatic Colorectal Cancer
- Fruquintinib alternating with Bevacizumab plus Capecitabine
- Bevacizumab plus Capecitabine
-
Guangzhou, Guangdong, ChinaNanfang Hospital, Southern Medical University
Jan 4, 2023
Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS=1) Trial (SG001 injection, Paclitaxel, Cisplatin)
Not yet recruiting
- Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
- SG001 injection
- +5 more
- (no location specified)
Jan 27, 2023